{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T19:45:53Z","timestamp":1791747953269,"version":"4.3.4"},"reference-count":168,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.clim.2026.110783","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:46:20Z","timestamp":1791319580000},"page":"110783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ex vivo expansion reshapes invariant natural killer T-cell state, function, and therapeutic fitness"],"prefix":"10.1016","volume":"288","author":[{"given":"Naeimeh","family":"Tavakolinia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2026.110783_bb0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1653183","article-title":"Innate iNKT cells: from biological insight to clinical impact","volume":"16","author":"Rotolo","year":"2025","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2026.110783_bb0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.smim.2009.10.004","article-title":"Antigen recognition by CD1d-restricted NKT T cell receptors","volume":"22","author":"Godfrey","year":"2010","journal-title":"Semin. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0015","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/nprot.2007.515","article-title":"Methods for detection, isolation and culture of mouse and human invariant NKT cells","volume":"3","author":"Watarai","year":"2008","journal-title":"Nat. Protoc."},{"issue":"6","key":"10.1016\/j.clim.2026.110783_bb0020","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1038\/sj.leu.2402943","article-title":"Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells","volume":"17","author":"Metelitsa","year":"2003","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clim.2026.110783_bb0025","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1084\/jem.20030324","article-title":"Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein","volume":"198","author":"Fujii","year":"2003","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.clim.2026.110783_bb0030","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1084\/jem.20042280","article-title":"Sequential activation of NKT cells and NK cells provides effective innate immunotherapy of cancer","volume":"201","author":"Smyth","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2026.110783_bb0035","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1600-065X.2007.00561.x","article-title":"Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity","volume":"220","author":"Fujii","year":"2007","journal-title":"Immunol. Rev."},{"issue":"8","key":"10.1016\/j.clim.2026.110783_bb0040","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood.2022016201","article-title":"Natural killer T cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy","volume":"141","author":"Courtney","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110783_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1625426","article-title":"CAR-iNKT cells: redefining the frontiers of cellular immunotherapy","volume":"16","author":"Niedzielska","year":"2025","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2026.110783_bb0050","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/blood.2025029302","article-title":"Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia","volume":"147","author":"Ren","year":"2026","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clim.2026.110783_bb0055","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1038\/s41375-026-02930-5","article-title":"Synergizing hypomethylating agents with off-the-shelf CD70-targeted chimeric antigen receptor-engineered natural killer T cells for the treatment of acute myeloid leukemia","volume":"40","author":"Li","year":"2026","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clim.2026.110783_bb0060","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1537-2995.2009.02395.x","article-title":"Adoptive therapy by transfusing expanded donor murine natural killer T cells can suppress acute graft-versus-host disease in allogeneic bone marrow transplantation","volume":"50","author":"Yang","year":"2010","journal-title":"Transfusion"},{"issue":"11","key":"10.1016\/j.clim.2026.110783_bb0065","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2010-08-303008","article-title":"Low doses of natural killer T cells provide protection from acute graft-versus-host disease via an IL-4-dependent mechanism","volume":"117","author":"Leveson-Gower","year":"2011","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.clim.2026.110783_bb0070","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1182\/blood-2014-05-576017","article-title":"CD4+ invariant natural killer T cells protect from murine GVHD lethality through expansion of donor CD4+CD25+FoxP3+ regulatory T cells","volume":"124","author":"Schneidawind","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.clim.2026.110783_bb0075","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1182\/blood-2014-11-612762","article-title":"Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality","volume":"125","author":"Schneidawind","year":"2015","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clim.2026.110783_bb0080","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1182\/blood-2011-11-389304","article-title":"Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation","volume":"119","author":"Chaidos","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2567.2007.02647.x","article-title":"Characterization of human invariant natural killer T subsets in health and disease using a novel invariant natural killer T cell-clonotypic monoclonal antibody, 6B11","volume":"122","author":"Montoya","year":"2007","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0090","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ijc.20998","article-title":"Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load","volume":"116","author":"Molling","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.clim.2026.110783_bb0095","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-1-0716-1775-5_11","article-title":"Expansion of human iNKT cells ex vivo","volume":"2388","author":"Wang","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.clim.2026.110783_bb0100","first-page":"67","article-title":"Human and mouse iNKT cell expansion and engineering with viral vectors","volume":"196","author":"Delfanti","year":"2025","journal-title":"Methods Cell Biol."},{"issue":"3","key":"10.1016\/j.clim.2026.110783_bb0105","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/01.cji.0000199197.35964.8a","article-title":"Efficient ex vivo expansion of Valpha24+ NKT cells derived from G-CSF-mobilized blood cells","volume":"29","author":"Imataki","year":"2006","journal-title":"J. Immunother."},{"issue":"1\u20132","key":"10.1016\/j.clim.2026.110783_bb0110","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0022-1759(00)00272-6","article-title":"Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15","volume":"247","author":"van der Vliet","year":"2001","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.clim.2026.110783_bb0115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1471-2172-9-71","article-title":"Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide","volume":"9","author":"Croudace","year":"2008","journal-title":"BMC Immunol."},{"key":"10.1016\/j.clim.2026.110783_bb0120","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3389\/fimmu.2018.01519","article-title":"CD1d-invariant natural killer T cell-based Cancer immunotherapy: alpha-galactosylceramide and beyond","volume":"9","author":"King","year":"2018","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.clim.2026.110783_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261727","article-title":"Expansion of invariant natural killer T cells from systemic lupus erythematosus patients by alpha-Galactosylceramide and IL-15","volume":"16","author":"Hsu","year":"2021","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.clim.2026.110783_bb0130","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.jcyt.2018.05.007","article-title":"Rapid ex vivo expansion of highly enriched human invariant natural killer T cells via single antigenic stimulation for cell therapy to prevent graft-versus-host disease","volume":"20","author":"Trujillo-Ocampo","year":"2018","journal-title":"Cytotherapy"},{"issue":"6","key":"10.1016\/j.clim.2026.110783_bb0135","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/eji.200737389","article-title":"Selective activation, expansion, and monitoring of human iNKT cells with a monoclonal antibody specific for the TCR alpha-chain CDR3 loop","volume":"38","author":"Exley","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2026.110783_bb0140","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.567406","article-title":"IL-7 during antigenic stimulation using allogeneic dendritic cells promotes expansion of CD45RA(\u2212)CD62L(+)CD4(+) invariant NKT cells with Th-2 biased cytokine production profile","volume":"11","author":"Trujillo-Ocampo","year":"2020","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.clim.2026.110783_bb0145","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/01.cji.0000163593.66910.ad","article-title":"Expansion of alpha-galactosylceramide-stimulated Valpha24+ NKT cells cultured in the absence of animal materials","volume":"28","author":"Harada","year":"2005","journal-title":"J. Immunother."},{"issue":"R1","key":"10.1016\/j.clim.2026.110783_bb0150","doi-asserted-by":"crossref","first-page":"R48","DOI":"10.1093\/hmg\/ddn079","article-title":"Good manufacturing practice and clinical-grade human embryonic stem cell lines","volume":"17","author":"Unger","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.clim.2026.110783_bb0155","article-title":"Artificial antigen presenting cell (aAPC) mediated activation and expansion of natural killer T cells","volume":"70","author":"East","year":"2012","journal-title":"J. Vis. Exp."},{"issue":"6","key":"10.1016\/j.clim.2026.110783_bb0160","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1172\/JCI83476","article-title":"CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo","volume":"126","author":"Tian","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0165","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/imr.12129","article-title":"Human cell-based artificial antigen-presenting cells for cancer immunotherapy","volume":"257","author":"Butler","year":"2014","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0170","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/imr.12793","article-title":"Cellular therapy: adoptive immunotherapy with expanded natural killer cells","volume":"290","author":"Lee","year":"2019","journal-title":"Immunol. Rev."},{"issue":"9","key":"10.1016\/j.clim.2026.110783_bb0175","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1158\/0008-5472.CAN-08-3712","article-title":"Expansion of highly cytotoxic human natural killer cells for cancer cell therapy","volume":"69","author":"Fujisaki","year":"2009","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.clim.2026.110783_bb0180","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jcyt.2017.12.014","article-title":"Large-scale expansion of Vgamma9Vdelta2 T cells with engineered K562 feeder cells in G-rex vessels and their use as chimeric antigen receptor-modified effector cells","volume":"20","author":"Xiao","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.clim.2026.110783_bb0185","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3389\/fmed.2018.00150","article-title":"Industrializing autologous adoptive immunotherapies: manufacturing advances and challenges","volume":"5","author":"Iyer","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.clim.2026.110783_bb0190","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3389\/fimmu.2017.01371","article-title":"Good manufacturing practice-compliant production and lot-release of ex vivo expanded regulatory T cells as basis for treatment of patients with autoimmune and inflammatory disorders","volume":"8","author":"Wiesinger","year":"2017","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0195","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1186\/s12967-025-06400-x","article-title":"Surveying local CAR T-cell manufacturing processes to facilitate standardization and expand accessibility","volume":"23","author":"Gupta","year":"2025","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0200","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.nano.2013.06.015","article-title":"Nanoscale artificial antigen presenting cells for T cell immunotherapy","volume":"10","author":"Perica","year":"2014","journal-title":"Nanomedicine"},{"issue":"5","key":"10.1016\/j.clim.2026.110783_bb0205","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jcyt.2020.01.011","article-title":"Expansion and CD2\/CD3\/CD28 stimulation enhance Th2 cytokine secretion of human invariant NKT cells with retained anti-tumor cytotoxicity","volume":"22","author":"Andrews","year":"2020","journal-title":"Cytotherapy"},{"issue":"7","key":"10.1016\/j.clim.2026.110783_bb0210","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jcyt.2024.03.003","article-title":"CAR-T cell expansion platforms yield distinct T cell differentiation states","volume":"26","author":"Song","year":"2024","journal-title":"Cytotherapy"},{"issue":"12","key":"10.1016\/j.clim.2026.110783_bb0215","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1002\/stem.2465","article-title":"Efficient regeneration of human Valpha24(+) invariant natural killer T cells and their anti-tumor activity in vivo","volume":"34","author":"Yamada","year":"2016","journal-title":"Stem Cells"},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0220","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41232-023-00275-5","article-title":"Regeneration of invariant natural killer T (iNKT) cells: application of iPSC technology for iNKT cell-targeted tumor immunotherapy","volume":"43","author":"Aoki","year":"2023","journal-title":"Inflamm. Regen."},{"issue":"2","key":"10.1016\/j.clim.2026.110783_bb0225","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.stemcr.2016.01.005","article-title":"Cellular adjuvant properties, direct cytotoxicity of re-differentiated Valpha24 invariant NKT-like cells from human induced pluripotent stem cells","volume":"6","author":"Kitayama","year":"2016","journal-title":"Stem Cell Rep."},{"issue":"10","key":"10.1016\/j.clim.2026.110783_bb0230","doi-asserted-by":"crossref","DOI":"10.21769\/BioProtoc.2277","article-title":"Efficient production of functional human NKT cells from induced pluripotent stem cells - reprogramming of human Valpha24(+)iNKT cells","volume":"7","author":"Yamada","year":"2017","journal-title":"Bio-Protoc."},{"issue":"4","key":"10.1016\/j.clim.2026.110783_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2025.102036","article-title":"Development of a practical GMP-compliant manufacturing process for T cell-derived induced pluripotent stem cells","volume":"28","author":"Hulspas","year":"2026","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0240","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-66801-w","article-title":"Allogeneic iPSC-derived iNKT cells in recurrent head and neck cancer: a phase 1 trial","volume":"16","author":"Iinuma","year":"2025","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.clim.2026.110783_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000402","article-title":"Innate-like control of human iNKT cell autoreactivity via the hypervariable CDR3beta loop","volume":"8","author":"Matulis","year":"2010","journal-title":"PLoS Biol."},{"key":"10.1016\/j.clim.2026.110783_bb0250","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jaut.2015.12.005","article-title":"CDR3beta sequence motifs regulate autoreactivity of human invariant NKT cell receptors","volume":"68","author":"Chamoto","year":"2016","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.clim.2026.110783_bb0255","first-page":"8","article-title":"Tissue-specific shaping of the TCR repertoire and antigen specificity of iNKT cells","author":"Jimeno","year":"2019","journal-title":"Elife"},{"issue":"9","key":"10.1016\/j.clim.2026.110783_bb0260","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/ni.2076","article-title":"Recognition of beta-linked self glycolipids mediated by natural killer T cell antigen receptors","volume":"12","author":"Pellicci","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.clim.2026.110783_bb0265","article-title":"Adoptive immunotherapy with engineered iNKT cells to target cancer cells and the suppressive microenvironment","volume":"9","author":"Delfanti","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"10.1016\/j.clim.2026.110783_bb0270","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.stem.2019.08.004","article-title":"Development of hematopoietic stem cell-engineered invariant natural killer T cell therapy for cancer","volume":"25","author":"Zhu","year":"2019","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0275","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13287-022-02787-2","article-title":"Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention","volume":"13","author":"Li","year":"2022","journal-title":"Stem Cell Res. Ther."},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0280","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-025-01736-9","article-title":"Targeting triple-negative breast cancer using cord-blood CD34(+) HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity","volume":"18","author":"Li","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.clim.2026.110783_bb0285","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.4237","article-title":"Generation of mature T cells from human hematopoietic stem and progenitor cells in artificial thymic organoids","volume":"14","author":"Seet","year":"2017","journal-title":"Nat. Methods"},{"issue":"11","key":"10.1016\/j.clim.2026.110783_bb0290","article-title":"Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy","volume":"2","author":"Li","year":"2021","journal-title":"Cell Rep. Med."},{"issue":"3","key":"10.1016\/j.clim.2026.110783_bb0295","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8030288","article-title":"iPS-cell technology and the problem of genetic instability-can it ever be safe for clinical use?","volume":"8","author":"Attwood","year":"2019","journal-title":"J. Clin. Med."},{"issue":"6","key":"10.1016\/j.clim.2026.110783_bb0300","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/stmcls\/sxac020","article-title":"Human induced pluripotent stem cells: from cell origin, genomic stability, and epigenetic memory to translational medicine","volume":"40","author":"Poetsch","year":"2022","journal-title":"Stem Cells"},{"issue":"9","key":"10.1016\/j.clim.2026.110783_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.104859","article-title":"Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers","volume":"25","author":"Li","year":"2022","journal-title":"iScience"},{"issue":"3","key":"10.1016\/j.clim.2026.110783_bb0310","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41587-024-02226-y","article-title":"Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method","volume":"43","author":"Li","year":"2025","journal-title":"Nat. Biotechnol."},{"issue":"9","key":"10.1016\/j.clim.2026.110783_bb0315","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1093\/intimm\/dxh292","article-title":"Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs","volume":"17","author":"Osada","year":"2005","journal-title":"Int. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2026.110783_bb0320","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cyto.2015.09.015","article-title":"Interleukin-15 enhances the expansion and function of natural killer T cells from adult peripheral and umbilical cord blood","volume":"76","author":"Lin","year":"2015","journal-title":"Cytokine"},{"issue":"7","key":"10.1016\/j.clim.2026.110783_bb0325","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.4049\/jimmunol.1800429","article-title":"IL-21 selectively protects CD62L(+) NKT cells and enhances their effector functions for adoptive immunotherapy","volume":"201","author":"Ngai","year":"2018","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.clim.2026.110783_bb0330","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0014374","article-title":"Alpha-galactosylceramide analogs with weak agonist activity for human iNKT cells define new candidate anti-inflammatory agents","volume":"5","author":"Bricard","year":"2010","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.clim.2026.110783_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028648","article-title":"Distinct and overlapping effector functions of expanded human CD4+, CD8alpha+ and CD4-CD8alpha- invariant natural killer T cells","volume":"6","author":"O'Reilly","year":"2011","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.clim.2026.110783_bb0340","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/eji.200737838","article-title":"Distinct subsets of human invariant NKT cells differentially regulate T helper responses via dendritic cells","volume":"38","author":"Liu","year":"2008","journal-title":"Eur. J. Immunol."},{"issue":"18","key":"10.1016\/j.clim.2026.110783_bb0345","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1182\/blood-2013-11-541235","article-title":"Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy","volume":"124","author":"Heczey","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110783_bb0350","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3389\/fimmu.2020.00873","article-title":"Enhancing neuroblastoma immunotherapies by engaging iNKT and NK cells","volume":"11","author":"McNerney","year":"2020","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.clim.2026.110783_bb0355","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.4049\/jimmunol.178.5.2827","article-title":"IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production","volume":"178","author":"Coquet","year":"2007","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.clim.2026.110783_bb0360","doi-asserted-by":"crossref","first-page":"5758","DOI":"10.4049\/jimmunol.1003043","article-title":"Proinflammatory environment dictates the IL-17-producing capacity of human invariant NKT cells","volume":"186","author":"Moreira-Teixeira","year":"2011","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2026.110783_bb0365","doi-asserted-by":"crossref","first-page":"624","DOI":"10.4049\/jimmunol.1102281","article-title":"Rapamycin combined with TGF-beta converts human invariant NKT cells into suppressive Foxp3+ regulatory cells","volume":"188","author":"Moreira-Teixeira","year":"2012","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.clim.2026.110783_bb0370","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1084\/jem.20102555","article-title":"Innate and cytokine-driven signals, rather than microbial antigens, dominate in natural killer T cell activation during microbial infection","volume":"208","author":"Brigl","year":"2011","journal-title":"J. Exp. Med."},{"issue":"5","key":"10.1016\/j.clim.2026.110783_bb0375","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.4049\/jimmunol.178.5.2706","article-title":"Invariant NKT cells amplify the innate immune response to lipopolysaccharide","volume":"178","author":"Nagarajan","year":"2007","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.clim.2026.110783_bb0380","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1084\/jem.20111024","article-title":"Human invariant natural killer T cells acquire transient innate responsiveness via histone H4 acetylation induced by weak TCR stimulation","volume":"209","author":"Wang","year":"2012","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0385","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1046\/j.1365-2567.2003.01701.x","article-title":"Interleukin-12 and interleukin-2-induced invariant natural killer T-cell cytokine secretion and perforin expression independent of T-cell receptor activation","volume":"110","author":"Hou","year":"2003","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0390","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41467-023-44310-y","article-title":"IL-12 reprograms CAR-expressing natural killer T cells to long-lived Th1-polarized cells with potent antitumor activity","volume":"15","author":"Landoni","year":"2024","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.clim.2026.110783_bb0395","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/intimm\/dxn060","article-title":"IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells","volume":"20","author":"Smithgall","year":"2008","journal-title":"Int. Immunol."},{"key":"10.1016\/j.clim.2026.110783_bb0400","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.3389\/fimmu.2019.01126","article-title":"Alpha-GalCer and iNKT cell-based Cancer immunotherapy: realizing the therapeutic potentials","volume":"10","author":"Zhang","year":"2019","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.clim.2026.110783_bb0405","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.4049\/jimmunol.165.8.4367","article-title":"Fas\/Fas ligand interactions promote activation-induced cell death of NK T lymphocytes","volume":"165","author":"Leite-de-Moraes","year":"2000","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.clim.2026.110783_bb0410","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1172\/JCI24762","article-title":"Glycolipid antigen induces long-term natural killer T cell anergy in mice","volume":"115","author":"Parekh","year":"2005","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.clim.2026.110783_bb0415","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/intimm\/dxq444","article-title":"Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation","volume":"22","author":"Iyoda","year":"2010","journal-title":"Int. Immunol."},{"issue":"4","key":"10.1016\/j.clim.2026.110783_bb0420","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.4049\/jimmunol.1302623","article-title":"Alpha-Galactosylceramide but not phenyl-glycolipids induced NKT cell anergy and IL-33-mediated myeloid-derived suppressor cell accumulation via upregulation of egr2\/3","volume":"192","author":"Huang","year":"2014","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.clim.2026.110783_bb0425","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S1074-7613(00)80566-X","article-title":"Biochemical mechanisms of IL-2-regulated Fas-mediated T cell apoptosis","volume":"8","author":"Refaeli","year":"1998","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.clim.2026.110783_bb0430","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.4049\/jimmunol.1500203","article-title":"Selective conditions are required for the induction of invariant NKT cell hyporesponsiveness by antigenic stimulation","volume":"195","author":"Wingender","year":"2015","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.clim.2026.110783_bb0435","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.4049\/jimmunol.167.7.4046","article-title":"Loss of IFN-gamma production by invariant NK T cells in advanced cancer","volume":"167","author":"Tahir","year":"2001","journal-title":"J. Immunol."},{"issue":"12","key":"10.1016\/j.clim.2026.110783_bb0440","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1084\/jem.20021650","article-title":"A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma","volume":"197","author":"Dhodapkar","year":"2003","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.clim.2026.110783_bb0445","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1172\/JCI72308","article-title":"IL-10-producing NKT10 cells are a distinct regulatory invariant NKT cell subset","volume":"124","author":"Sag","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.clim.2026.110783_bb0450","first-page":"11","article-title":"Longitudinal analysis of invariant natural killer T cell activation reveals a cMAF-associated transcriptional state of NKT10 cells","author":"Kane","year":"2022","journal-title":"Elife"},{"issue":"34","key":"10.1016\/j.clim.2026.110783_bb0455","doi-asserted-by":"crossref","first-page":"12474","DOI":"10.1073\/pnas.1406240111","article-title":"KLRG+ invariant natural killer T cells are long-lived effectors","volume":"111","author":"Shimizu","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.clim.2026.110783_bb0460","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.4049\/jimmunol.0803648","article-title":"PD-1\/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells","volume":"182","author":"Parekh","year":"2009","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.clim.2026.110783_bb0465","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1002\/eji.201243185","article-title":"Invariant natural killer T (iNKT) cell exhaustion in sarcoidosis","volume":"43","author":"Snyder-Cappione","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2026.110783_bb0470","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12977-015-0142-z","article-title":"Elevated expression of LAG-3, but not PD-1, is associated with impaired iNKT cytokine production during chronic HIV-1 infection and treatment","volume":"12","author":"Juno","year":"2015","journal-title":"Retrovirology"},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0475","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-36468-8","article-title":"The effect of blocking immune checkpoints LAG-3 and PD-1 on human invariant natural killer T cell function","volume":"13","author":"Balasko","year":"2023","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.clim.2026.110783_bb0480","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","article-title":"Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat. Med."},{"issue":"25","key":"10.1016\/j.clim.2026.110783_bb0485","doi-asserted-by":"crossref","first-page":"12410","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8(+) T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7764","key":"10.1016\/j.clim.2026.110783_bb0490","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41586-019-1325-x","article-title":"TOX transcriptionally and epigenetically programs CD8(+) T cell exhaustion","volume":"571","author":"Khan","year":"2019","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0495","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","article-title":"Intratumoral Tcf1(+)PD-1(+)CD8(+) T cells with stem-like properties promote tumor control in response to vaccination and checkpoint blockade immunotherapy","volume":"50","author":"Siddiqui","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2026.110783_bb0500","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.700374","article-title":"Distinct bioenergetic features of human invariant natural killer T cells enable retained functions in nutrient-deprived states","volume":"12","author":"Khurana","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110783_bb0505","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.3389\/fimmu.2018.01192","article-title":"Immunometabolic activation of invariant natural killer T cells","volume":"9","author":"Ververs","year":"2018","journal-title":"Front. Immunol."},{"issue":"16","key":"10.1016\/j.clim.2026.110783_bb0510","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1158\/1078-0432.CCR-12-2169","article-title":"beta-mannosylceramide activates type I natural killer t cells to induce tumor immunity without inducing long-term functional anergy","volume":"19","author":"O\u2019Konek","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.clim.2026.110783_bb0515","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.4049\/jimmunol.1701801","article-title":"Elevated hepatic CD1d levels coincide with invariant NKT cell defects in chronic hepatitis B virus infection","volume":"200","author":"Tan","year":"2018","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.108597","article-title":"IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects","volume":"27","author":"Liu","year":"2024","journal-title":"iScience"},{"issue":"4","key":"10.1016\/j.clim.2026.110783_bb0525","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1016\/j.ymthe.2026.01.001","article-title":"IL-18 metabolically reprograms CAR-expressing natural killer T cells and enhances their antitumor activity","volume":"34","author":"Barragan Bravo","year":"2026","journal-title":"Mol. Ther."},{"issue":"2","key":"10.1016\/j.clim.2026.110783_bb0530","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1158\/2326-6066.CIR-22-0333","article-title":"LEF1 drives a central memory program and supports antitumor activity of natural killer T cells","volume":"11","author":"Ngai","year":"2023","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.clim.2026.110783_bb0535","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/2326-6066.CIR-24-0259","article-title":"PRDM1 is a key regulator of the NKT-cell central memory program and effector function","volume":"13","author":"Tian","year":"2025","journal-title":"Cancer Immunol. Res."},{"issue":"11","key":"10.1016\/j.clim.2026.110783_bb0540","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat. Med."},{"issue":"74","key":"10.1016\/j.clim.2026.110783_bb0545","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn6563","article-title":"TCR-engineered iNKT cells induce robust antitumor response by dual targeting cancer and suppressive myeloid cells","volume":"7","author":"Delfanti","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.clim.2026.110783_bb0550","doi-asserted-by":"crossref","DOI":"10.1017\/S1462399408000732","article-title":"CD1d-restricted glycolipid antigens: presentation principles, recognition logic and functional consequences","volume":"10","author":"Florence","year":"2008","journal-title":"Expert Rev. Mol. Med."},{"issue":"7","key":"10.1016\/j.clim.2026.110783_bb0555","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1111\/cas.14428","article-title":"Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner","volume":"111","author":"Aoki","year":"2020","journal-title":"Cancer Sci."},{"key":"10.1016\/j.clim.2026.110783_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2022.101342","article-title":"iNKT: a new avenue for CAR-based cancer immunotherapy","volume":"17","author":"Liu","year":"2022","journal-title":"Transl. Oncol."},{"issue":"10","key":"10.1016\/j.clim.2026.110783_bb0565","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"issue":"12","key":"10.1016\/j.clim.2026.110783_bb0570","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1016\/j.ymthe.2025.09.026","article-title":"Allogeneic stem cell-engineered EGFRvIII-specific CAR-NKT cells for treating glioblastoma with enhanced efficacy and safety","volume":"33","author":"Li","year":"2025","journal-title":"Mol. Ther."},{"issue":"23","key":"10.1016\/j.clim.2026.110783_bb0575","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","article-title":"NKT cells Coexpressing a GD2-specific chimeric antigen receptor and IL15 show enhanced in vivo persistence and antitumor activity against neuroblastoma","volume":"25","author":"Xu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2026.110783_bb0580","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1436968","article-title":"Traversing the bench to bedside journey for iNKT cell therapies","volume":"15","author":"O\u2019Neal","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0585","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s12967-020-02526-2","article-title":"Lentiviral delivery of combinatorial CAR\/CRISPRi circuit into human primary T cells is enhanced by TBK1\/IKKvarepsilon complex inhibitor BX795","volume":"18","author":"Li","year":"2020","journal-title":"J. Transl. Med."},{"issue":"19\u201320","key":"10.1016\/j.clim.2026.110783_bb0590","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1089\/hum.2021.173","article-title":"Choosing the right tool for genetic engineering: clinical lessons from chimeric antigen receptor-T cells","volume":"32","author":"Irving","year":"2021","journal-title":"Hum. Gene Ther."},{"issue":"8","key":"10.1016\/j.clim.2026.110783_bb0595","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19082365","article-title":"The generation of CAR-transfected natural killer T cells for the immunotherapy of melanoma","volume":"19","author":"Simon","year":"2018","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.clim.2026.110783_bb0600","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11081198","article-title":"Clinical-scale production of CAR-T cells for the treatment of melanoma patients by mRNA transfection of a CSPG4-specific CAR under full GMP compliance","volume":"11","author":"Wiesinger","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"7714","key":"10.1016\/j.clim.2026.110783_bb0605","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41586-018-0326-5","article-title":"Reprogramming human T cell function and specificity with non-viral genome targeting","volume":"559","author":"Roth","year":"2018","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.clim.2026.110783_bb0610","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.clim.2026.110783_bb0615","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.clim.2026.110783_bb0620","first-page":"3153","article-title":"Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction","volume":"141","author":"Selli","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clim.2026.110783_bb0625","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-1-0716-1775-5_13","article-title":"Ex vivo expansion of Th2-polarizing immunotherapeutic iNKT cells from human peripheral blood","volume":"2388","author":"Khatwani","year":"2021","journal-title":"Methods Mol. Biol."},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0630","first-page":"1","article-title":"Comparison of two flow cytometric methods for detection of human invariant natural killer T cells (iNKT)","volume":"7","author":"Fereidouni","year":"2010","journal-title":"Iran. J. Immunol."},{"key":"10.1016\/j.clim.2026.110783_bb0635","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1441634","article-title":"Thymic development of human natural killer T cells: recent advances and implications for immunotherapy","volume":"15","author":"Pellicci","year":"2024","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.clim.2026.110783_bb0640","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/eji.200425958","article-title":"Limited correlation between human thymus and blood NKT cell content revealed by an ontogeny study of paired tissue samples","volume":"35","author":"Berzins","year":"2005","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0645","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/cei.12045","article-title":"Ex-vivo analysis of human natural killer T cells demonstrates heterogeneity between tissues and within established CD4(+) and CD4(\u2212) subsets","volume":"172","author":"Chan","year":"2013","journal-title":"Clin. Exp. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0650","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2001-12-0196","article-title":"Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity","volume":"100","author":"Kim","year":"2002","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clim.2026.110783_bb0655","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.4049\/jimmunol.171.5.2571","article-title":"CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells","volume":"171","author":"Thomas","year":"2003","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.clim.2026.110783_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114705","article-title":"Unraveling the phenotypic states of human innate-like T cells: comparative insights with conventional T cells and mouse models","volume":"43","author":"Loh","year":"2024","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.clim.2026.110783_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115587","article-title":"Single-cell transcriptomic profiling reveals diversity in human iNKT cells across hematologic tissues","volume":"44","author":"Jayasinghe","year":"2025","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.clim.2026.110783_bb0670","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.4049\/jimmunol.1202223","article-title":"Human invariant NKT cell subsets differentially promote differentiation, antibody production, and T cell stimulation by B cells in vitro","volume":"191","author":"Zeng","year":"2013","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.clim.2026.110783_bb0675","doi-asserted-by":"crossref","first-page":"5140","DOI":"10.4049\/jimmunol.0711086","article-title":"Enrichment of human CD4+ V(alpha)24\/Vbeta11 invariant NKT cells in intrahepatic malignant tumors","volume":"182","author":"Bricard","year":"2009","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.clim.2026.110783_bb0680","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/jleuko\/qiad113","article-title":"Single-cell transcriptomics reveal different maturation stages and sublineage commitment of human thymic invariant natural killer T cells","volume":"115","author":"Maas-Bauer","year":"2024","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.clim.2026.110783_bb0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216149","article-title":"scRNA-Seq and imaging mass cytometry analyses unveil iNKT cells-mediated anti-tumor immunity in pancreatic cancer liver metastasis","volume":"561","author":"Yi","year":"2023","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.clim.2026.110783_bb0690","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/imcb.70074","article-title":"Expression of CD38 on resting peripheral iNKT cells defines an immature subpopulation with distinct functionality in humans","volume":"104","author":"Menne","year":"2026","journal-title":"Immunol. Cell Biol."},{"issue":"6","key":"10.1016\/j.clim.2026.110783_bb0695","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1111\/imcb.12248","article-title":"The peripheral differentiation of human natural killer T cells","volume":"97","author":"Liu","year":"2019","journal-title":"Immunol. Cell Biol."},{"issue":"4","key":"10.1016\/j.clim.2026.110783_bb0700","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood-2012-09-456095","article-title":"Human iNKT and MAIT cells exhibit a PLZF-dependent proapoptotic propensity that is counterbalanced by XIAP","volume":"121","author":"Gerart","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clim.2026.110783_bb0705","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/s41388-024-02948-y","article-title":"Overcoming resistance to programmed cell death protein 1 (PD-1) blockade with allogeneic invariant natural killer T-cells (iNKT)","volume":"43","author":"Hadfield","year":"2024","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0710","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41467-024-44905-z","article-title":"A phase 1\/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome","volume":"15","author":"Hammond","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2026.110783_bb0715","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1457771","article-title":"Comparative assessment of autologous and allogeneic iNKT cell transfer in iNKT cell-based immunotherapy","volume":"15","author":"Takami","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0720","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevImmunol.2020036178","article-title":"Current challenges and strategies for chimeric antigen receptor-T-cell therapy for solid tumors","volume":"41","author":"Chen","year":"2021","journal-title":"Crit. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.clim.2026.110783_bb0725","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1080\/08820139.2022.2096463","article-title":"Barriers and opportunities for CAR T-cell targeting of solid tumors","volume":"51","author":"Conejo-Garcia","year":"2022","journal-title":"Immunol. Investig."},{"issue":"22","key":"10.1016\/j.clim.2026.110783_bb0730","article-title":"Tumor microenvironment immunosuppression: a roadblock to CAR T-cell advancement in solid tumors","volume":"11","author":"Johnson","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.clim.2026.110783_bb0735","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-026-01629-3","article-title":"Engineering an in vivo charging station for CAR-redirected invariant natural killer T cells to enhance cancer therapy","author":"Li","year":"2026","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.clim.2026.110783_bb0740","article-title":"Spatiotemporal profiling reveals distinct dynamics and checkpoint regulations of CAR-T and CAR-NKT cells against solid tumors","volume":"11","author":"Li","year":"2026","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.clim.2026.110783_bb0745","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/mt.2013.262","article-title":"Kinetics of tumor destruction by chimeric antigen receptor-modified T cells","volume":"22","author":"Anurathapan","year":"2014","journal-title":"Mol. Ther."},{"issue":"31","key":"10.1016\/j.clim.2026.110783_bb0750","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1038\/s41388-025-03491-0","article-title":"Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor","volume":"44","author":"Garmezy","year":"2025","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.clim.2026.110783_bb0755","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.jtct.2023.12.072","article-title":"Off-the-shelf CD19-specific CAR-NKT cells in patients with relapsed or refractory B-cell malignancies","volume":"30","author":"Ramos","year":"2024","journal-title":"Transplant. Cell. Ther."},{"issue":"Supplement 1","key":"10.1016\/j.clim.2026.110783_bb0760","doi-asserted-by":"crossref","first-page":"12699","DOI":"10.1182\/blood-2022-165516","article-title":"Pre-clinical evaluation of allogeneic \u2018off-the-shelf\u2019 CAR-iNKT cells targeting CD19 (ALA-101)-expressing hematological malignancies","volume":"140","author":"Ponnusamy","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clim.2026.110783_bb0765","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0342387","article-title":"A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and alpha-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: a study protocol","volume":"21","author":"Kurokawa","year":"2026","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.clim.2026.110783_bb0770","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.trecan.2025.03.001","article-title":"The clinical landscape of CAR-engineered unconventional T cells","volume":"11","author":"Li","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.clim.2026.110783_bb0775","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1186224","article-title":"Potency assays and biomarkers for cell-based advanced therapy medicinal products","volume":"14","author":"Capelli","year":"2023","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.clim.2026.110783_bb0780","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1158\/1078-0432.CCR-04-1453","article-title":"A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer","volume":"11","author":"Ishikawa","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"20 Pt 1","key":"10.1016\/j.clim.2026.110783_bb0785","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1158\/1078-0432.CCR-06-0114","article-title":"A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer","volume":"12","author":"Motohashi","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.clim.2026.110783_bb0790","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.4049\/jimmunol.0800126","article-title":"A phase I-II study of alpha-galactosylceramide-pulsed IL-2\/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer","volume":"182","author":"Motohashi","year":"2009","journal-title":"J. Immunol."},{"issue":"14","key":"10.1016\/j.clim.2026.110783_bb0795","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1158\/1078-0432.CCR-16-0600","article-title":"Adoptive transfer of invariant NKT cells as immunotherapy for advanced melanoma: a phase I clinical trial","volume":"23","author":"Exley","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1\u20132","key":"10.1016\/j.clim.2026.110783_bb0800","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jim.2012.05.019","article-title":"Ex-vivo alpha-galactosylceramide activation of NKT cells in humans and macaques","volume":"382","author":"Fernandez","year":"2012","journal-title":"J. Immunol. Methods"},{"issue":"6","key":"10.1016\/j.clim.2026.110783_bb0805","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1172\/JCI37869","article-title":"Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages","volume":"119","author":"Song","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.clim.2026.110783_bb0810","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101249","article-title":"Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence","volume":"32","author":"Cappabianca","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"6","key":"10.1016\/j.clim.2026.110783_bb0815","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/j.ymthe.2024.04.005","article-title":"Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy","volume":"32","author":"Li","year":"2024","journal-title":"Mol. Ther."},{"issue":"5","key":"10.1016\/j.clim.2026.110783_bb0820","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1182\/bloodadvances.2018028886","article-title":"Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein","volume":"3","author":"Das","year":"2019","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.clim.2026.110783_bb0825","first-page":"994","article-title":"Sustained activation and tumor targeting of NKT cells using a CD1d-anti-HER2-scFv fusion protein induce antitumor effects in mice","volume":"118","author":"Stirnemann","year":"2008","journal-title":"J. Clin. Invest."},{"issue":"Supplement 1","key":"10.1016\/j.clim.2026.110783_bb0830","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1182\/blood-2023-190598","article-title":"Development of novel invariant TCR-anchored bispecific engagers to enhance anti-cancer activity of iNKT cells","volume":"142","author":"Karaxhuku","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clim.2026.110783_bb0835","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s00262-012-1381-7","article-title":"CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses","volume":"62","author":"Corgnac","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.clim.2026.110783_bb0840","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1158\/0008-5472.CAN-20-2219","article-title":"Serial stimulation of invariant natural killer T cells with covalently stabilized bispecific T-cell engagers generates antitumor immunity while avoiding anergy","volume":"81","author":"Kharkwal","year":"2021","journal-title":"Cancer Res."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166162600121X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152166162600121X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T18:47:49Z","timestamp":1791744469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152166162600121X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":168,"alternative-id":["S152166162600121X"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2026.110783","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ex vivo expansion reshapes invariant natural killer T-cell state, function, and therapeutic fitness","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2026.110783","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110783"}}